3 results
First, to demonstrate whether Lanreotide attenuates progression of the renal phenotype in ADPKD patients as measured by change in rate of renal function decline and change in renal volume. Second, to demonstrate whether Lanreotide modifies…
Primary Objective(s)Phase I (completed)The primary objective of the Phase I portion of the study is to determine the maximum tolerated dose (MTD) of the combination of melflufen and dexamethasone in patients with relapsed/refractory multiple myeloma…
This study (AMYPAD Diagnostic and Patient Management Study) will determine in a real-life clinical setting for whom diagnostic amyloid PET imaging is appropriate, when this is best performed, and how the resulting information is influencing…